ArticleThe Journal of clinical investigation2005
Identification of human urinary trefoil factor 1 as a novel calcium oxalate crystal growth inhibitor.
Article in The Journal of clinical investigation, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 80 citations in OpenAlex.
- Lime powder treatment reduces urinary excretion of total protein and transferrin but increases uromodulin excretion in patients with urolithiasis.Urolithiasis · 2018Trial
- Proteomic Characterization of Bottlenose Dolphin (Journal of proteome research · 2026Article
- Advances in the mechanism of urinary proteins in calcium oxalate kidney stone formation.Urolithiasis · 2025Review
- Anion exchange chromatographic fractionation of urinary proteins followed by tandem mass spectrometry identifies potential natural inhibitors of calcium oxalate stone.Computational and structural biotechnology journal · 2025Article
- Association of functional genetic variants in TFF1 and nephrolithiasis risk in a Chinese population.BMC urology · 2022Article
- StoneMod: a database for kidney stone modulatory proteins with experimental evidence.Scientific reports · 2020Article
- Structure, Function, and Therapeutic Potential of the Trefoil Factor Family in the Gastrointestinal Tract.ACS pharmacology & translational science · 2020Review
- iTRAQ-Based Comparative Proteomics Analysis of Urolithiasis Rats Induced by Ethylene Glycol.BioMed research international · 2020Article
- Therapeutic potential of adenovirus-mediated TFF2-CTP-Flag peptide for treatment of colorectal cancer.Cancer gene therapy · 2019Article
- Differential proteomics of lesional vs. non-lesional biopsies revealed non-immune mechanisms of alopecia areata.Scientific reports · 2018Article
- Elongation factor Tu on Escherichia coli isolated from urine of kidney stone patients promotes calcium oxalate crystal growth and aggregation.Scientific reports · 2017Article
- Article
- In vitro inhibition of calcium oxalate crystallization and crystal adherence to renal tubular epithelial cells by Terminalia arjuna.Urolithiasis · 2016Article
- Mechanistic Insights into the Antilithiatic Proteins from Terminalia arjuna: A Proteomic Approach in Urolithiasis.PloS one · 2016Article
- Interstitial calcinosis in renal papillae of genetically engineered mouse models: relation to Randall's plaques.Urolithiasis · 2015Review
- Kidney stones: a fetal origins hypothesis.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2013Article
- Recurrent urolithiasis following parathyroidectomy for primary hyperparathyroidism.Annals of the Royal College of Surgeons of England · 2013Article
- Bacteria can promote calcium oxalate crystal growth and aggregation.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2013Article
- Circulating serum trefoil factor 3 (TFF3) is dramatically increased in chronic kidney disease.PloS one · 2013Article
- Nephrolithiasis: molecular mechanism of renal stone formation and the critical role played by modulators.BioMed research international · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Previous research on proteins that inhibit kidney stone formation has identified a relatively small number of well-characterized inhibitors. Identification of additional stone inhibitors would increase understanding of the pathogenesis and pathophysiology of nephrolithiasis. We have combined conventional biochemical methods with recent advances in mass spectrometry (MS) to identify a novel calcium oxalate (CaOx) crystal growth inhibitor in normal human urine. Anionic proteins were isolated by DEAE adsorption and separated by HiLoad 16/60 Superdex 75 gel filtration. A fraction with potent inhibitory activity against CaOx crystal growth was isolated and purified by anion exchange chromatography. The protein in 2 subfractions that retained inhibitory activity was identified by matrix-assisted laser desorption/ionization-time-of-flight MS and electrospray ionization-quadrupole-time-of-flight tandem MS as human trefoil factor 1 (TFF1). Western blot analysis confirmed the mass spectrometric protein identification. Functional studies of urinary TFF1 demonstrated that its inhibitory potency was similar to that of nephrocalcin. The inhibitory activity of urinary TFF1 was dose dependent and was inhibited by TFF1 antisera. Anti-C-terminal antibody was particularly effective, consistent with our proposed model in which the 4 C-terminal glutamic residues of TFF1 interact with calcium ions to prevent CaOx crystal growth. Concentrations and relative amounts of TFF1 in the urine of patients with idiopathic CaOx kidney stone were significantly less (2.5-fold for the concentrations and 5- to 22-fold for the relative amounts) than those found in controls. These data indicate that TFF1 is a novel potent CaOx crystal growth inhibitor with a potential pathophysiological role in nephrolithiasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.